FY2027 Earnings Estimate for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Investment analysts at Zacks Research raised their FY2027 earnings per share (EPS) estimates for shares of Bruker in a report issued on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $3.61 per share for the year, up from their prior forecast of $3.60. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%.

A number of other brokerages have also commented on BRKR. Barclays decreased their target price on Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Bank of America boosted their target price on Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, December 13th. The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price for the company in a research report on Thursday, December 5th. Stifel Nicolaus decreased their price objective on Bruker from $70.00 to $57.00 and set a “hold” rating for the company in a report on Friday, February 14th. Finally, Guggenheim reissued a “buy” rating on shares of Bruker in a report on Monday, February 24th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Bruker currently has an average rating of “Moderate Buy” and an average target price of $70.50.

Bruker Stock Performance

Shares of Bruker stock opened at $44.97 on Thursday. Bruker has a one year low of $44.11 and a one year high of $94.86. The firm has a market capitalization of $6.82 billion, a price-to-earnings ratio of 59.17, a PEG ratio of 2.16 and a beta of 1.18. The business has a 50-day simple moving average of $54.21 and a 200 day simple moving average of $58.66. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Monday, March 17th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend is Monday, March 17th. Bruker’s dividend payout ratio is presently 26.32%.

Hedge Funds Weigh In On Bruker

Several institutional investors have recently bought and sold shares of the company. FMR LLC lifted its stake in Bruker by 21.4% in the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock valued at $987,981,000 after purchasing an additional 2,521,904 shares during the last quarter. London Co. of Virginia lifted its stake in Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company’s stock valued at $245,820,000 after purchasing an additional 1,843,294 shares during the last quarter. State Street Corp lifted its stake in Bruker by 9.6% in the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock valued at $250,501,000 after purchasing an additional 318,808 shares during the last quarter. RTW Investments LP lifted its stake in Bruker by 1.1% in the third quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company’s stock valued at $240,406,000 after purchasing an additional 37,024 shares during the last quarter. Finally, Brown Advisory Inc. lifted its stake in Bruker by 10.1% in the fourth quarter. Brown Advisory Inc. now owns 2,026,712 shares of the medical research company’s stock valued at $118,806,000 after purchasing an additional 185,912 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.